BINEX Co., Ltd. Overview
BINEX is a Korean pharmaceutical company with two businesses: a legacy chemical-drug business and a biologics contract development and manufacturing (CDMO) business.
The chemical franchise is based in Busan. It sells about 120 generic and branded prescription products, led by the Biscan intestinal regulator and an ophthalmic eye-drop line, and also manufactures chemical drugs for other pharma companies on contract.
The biologics business runs two plants:
-
Songdo (Incheon): a government-owned facility that BINEX has operated under an entrusted-management contract since 2009, running to November 2029.
-
Osong (Chungbuk): acquired from Hanwha Chemical in 2015.
Together they hold roughly 11,000–12,000 L of mainly single-use mammalian capacity, focused on small-to-mid-scale, multi-product work.
BINEX describes itself as the first Korean biologics CMO. In January 2025 its Songdo plant obtained US FDA cGMP approval for Celltrion's tocilizumab biosimilar (Aptozma), having previously received EMA approval. The investment case depends on biologics overtaking the chemical business: biologics reached 48.5% of revenue in FY2025. It also depends on a KRW 55.7 bn, 10,000 L Osong expansion due in late 2026.
The balance sheet is stretched, and operating losses resumed from Q4 2025.
Company's own description (latest filings)
BINEX's Q1 2026 quarterly report (42nd fiscal period, filed 15 May 2026) divides the business into two segments [S1]:
-
Chemical pharmaceuticals: manufacture and sale of chemical drugs.
-
Biopharmaceuticals: contract development and manufacturing (CDMO) of biologics, plus R&D and testing services.
The report gives the period revenue mix as 56.5% chemical and 43.5% biologics [S1]. For Q2 2026, an aggregator citing the half-year report gives the mix as 57% pharma and 43% bio [S7].
Independent characterisation
| Stream | Share of total FY2021 revenue | Typical operating margin |
|---|---|---|
| Wholesale channel | 21.2% | About 12% (blended across products) |
| Retail channel | 12.6% | About 12% (blended across products) |
| Eye drops | 11.9% | About 12% (blended across products) |
| Contract chemical manufacturing for other pharma companies (수탁) | 10.8% | About 3–4% |
Chemical business. This is a mid-sized Korean generic and branded-generic business. It is regulated by the Ministry of Food and Drug Safety (MFDS) and depends on National Health Insurance (NHI) reimbursement. KIRS (2022) splits the chemical segment into four revenue streams [S4]:
Biologics CDMO business. BINEX positions itself as a flexible, multi-product mid-scale provider rather than a high-volume player like Samsung Biologics. KIRS describes the customer base as biotech companies with pipelines in clinical development [S4]. The 2025 commercialisation of Celltrion's tocilizumab biosimilar marks the shift from clinical-supply work to commercial-supply work [S2][S13].
Service scope runs from cell-line development and process and analytical development through to GMP drug substance (DS) and drug product (DP) fill/finish [S4][S27]. Disclosed modality experience includes [S27]:
-
Monoclonal antibodies
-
Bispecific antibodies
-
Fusion proteins
-
Plasmid DNA (pDNA)
Revenue model
| Revenue type | Description | Evidence |
|---|---|---|
| Product sales (chemical) | Branded generics and OTC/ETC products sold through wholesale and retail channels | [S4] |
| Contract manufacturing fees (chemical) | Toll manufacturing for other pharma marketers | [S4] |
| Contract manufacturing and development fees (biologics) | Batch-based DS/DP manufacturing, PPQ (process performance qualification) campaigns, development services. Disclosed payment terms: no upfront payment; billed after supply; paid within 45–60 business days. | [S14][S15] |
| Subscription / licensing | None material disclosed | — |
Value-chain position, customers and end markets
| Business | Value-chain position | Disclosed customers |
|---|---|---|
| Chemical | Vertically integrated manufacturer-marketer in Korea | Hospitals, clinics and pharmacies (via wholesale), plus other Korean pharma companies as CMO clients. In 2021, 32 consignment generics owned by 24 companies were made at the Busan No.1 plant [S20]. |
| Biologics | Outsourced manufacturing partner for drug owners | Historical: Genexine, ABL Bio, HanAll, Yuhan, Celltrion, Nichi-Iko, Boehringer Ingelheim, TRIGR, Roivant (spelled "Rovant" in source) [S4]. Recent: Celltrion (commercial tocilizumab DS and two clinical biosimilar DS) [S13]; undisclosed "global pharma" and "global biopharma" counterparties [S14][S15]; and a large domestic company that press speculated was Samsung Bioepis (unconfirmed) [S12]. |
| Year | Total customers | GMP products | DS batches | DP batches |
|---|---|---|---|---|
| FY2013 | 11 | 9 | 12 | 22 |
| FY2018 | 29 | 13 | 44 | 52 |
| FY2019 | 25 | 18 | 45 | 56 |
| FY2020 | 27 | 17 | 46 | 81 |
| FY2021 | 40 | 16 | 50 | 108 |
Customer counts for the biologics business [S4]:
Strategy
Stated strategic themes (paraphrased from company statements and filings)
-
Move from clinical supply to commercial CMO. BINEX aims to build commercial supply on the back of FDA and EMA approvals, starting with Celltrion biosimilars and extending to global clients [S13][S15].
-
Become a "multi-product, small-batch" specialist mid-scale CDMO. The company argues that mid-scale CDMOs suit the following trends, and highlights that few plants hold both FDA and EMA approvals [S11]:
-
ADCs and other new modalities
-
The obesity-drug development boom
-
Crowded antibody target classes
-
Customers' aversion to the write-off risk of large single-product runs
-
-
Benefit from reshoring away from Chinese CDMOs. Management expects US biotechs restricted from using Chinese CDMOs (the US Biosecure Act) to turn to Korea and Japan [S9][S19a].
-
Expand capacity ahead of demand. Management says Songdo and Osong are effectively fully booked, and is adding 10,000 L at Osong with further expansion planned on idle land [S11].
-
Diversify modality and service offering. An ADC CDMO package with Kyongbo [S27]; pDNA and microbial capability [S27].
Initiatives announced in the last 24 months
| Date | Initiative | Detail | Source |
|---|---|---|---|
| Jan 2025 | FDA cGMP approval (Songdo) | Prerequisite for US commercial supply. The company describes itself as the only Korean small/mid CDMO with FDA approval. | [S13][S36] |
| 14 Feb 2025 | Osong investment agreement with Chungbuk Province and Cheongju City | Press cites up to KRW 200 bn by 2029 and about 24,200 m² gross floor area (figures not confirmed by the company) | [S18][S12] |
| 19 Feb 2025 | Kyongbo Pharmaceutical ADC CDMO MOU | Joint end-to-end ADC package | [S27] |
| Jun 2025 | Celltrion follow-on clinical DS contract | Two biosimilar candidates | [S13] |
| 2,025 | Trade-show and business-development push | BIO USA 2025, INTERPHEX Week Tokyo 2025 | [S15] |
| 22 Sep 2025 | Osong +10,000 L commercial facility | About KRW 55.7 bn; construction began Sep 2025; target start-up Dec 2026; automation and digital QMS | [S10][S11] |
| 6 Nov 2025 | Financing: 7th EB (KRW 15.5 bn) | Treasury-share-backed, 115% exchange premium, used for facility investment | [S19][S1] |
| 2,026 | Osong FDA/EMA inspections | IBK expects inspections to become visible in H2 2026 after expansion completion | [S2] |
ESG or sustainability commitments: none disclosed in the sources reviewed.
Cost programmes with targets: none disclosed. Management said shutdown cadence will move from annual to once every three years, which reduces lost production days [S2].
Medium-term targets and guidance
BINEX does not publish formal numeric revenue or margin guidance in the sources reviewed. Statements made instead:
-
Management expected revenue growth to continue after Osong completion and cGMP certification from H2 2026 [S10][S19a].
-
At announcement, the company pointed to a backlog of more than KRW 100 bn (Sep 2025) to fund the expansion [S10].
Products & Services
Chemical pharmaceuticals segment
| Product / line | Description | Target customer | Notes / source |
|---|---|---|---|
| Biscan (비스칸) intestinal regulator | Probiotic based on Bacillus licheniformis. Strain registered in 1997; 2007 sales target KRW 5 bn. Since 2014, about 90% share of the ETC intestinal-regulator market for this ingredient. | Hospitals and clinics (ETC) | Flagship [S4][S21] |
| Ophthalmic (eye-drop) line | Eye drops; a "major player" in Korea's concentrated eye-drop market | Hospitals and pharmacies | 11.9% of FY2021 revenue [S4] |
| Amorin Tab. (아모린정) | Glimepiride (antidiabetic) | ETC | One of six products suspended in Mar 2021 [S20] |
| Selectin Cap. / Selectin Cap. 10 mg (셀렉틴캡슐) | Fluoxetine HCl (antidepressant) | ETC | Suspended in Mar 2021 [S20] |
| Daxpen Tab. (닥스펜정) | Dexibuprofen (NSAID) | ETC | Suspended in Mar 2021 [S20] |
| Ropsin Tab. 250 mg (로프신정) | Ciprofloxacin (antibiotic) | ETC | Suspended in Mar 2021 [S20] |
| Cadil Tab. 1 mg (카딜정) | Doxazosin mesylate (antihypertensive) | ETC | Suspended in Mar 2021 [S20] |
| Broader therapeutic catalogue | GI regulators and antispasmodics, antiemetics, antihistamines, laxatives, antihypertensive and urinary agents, antibacterials and antibiotics, cough/cold, antidiabetics, ophthalmics, vitamins and nutrients, ointments and creams | ETC and OTC | Morningstar business description [S29a] |
| Contract chemical manufacturing (수탁) | Toll manufacturing for other license holders | Korean pharma companies | 10.8% of FY2021 revenue; operating margin about 3–4% [S4] |
The company carries about 120 chemical products [S4]. A product-by-product revenue breakdown is not publicly disclosed in the sources reviewed. Launch years and prices are set by NHI listing and are not disclosed product by product.
Biopharmaceuticals (CDMO) segment
| Service / platform | Capability | Specification | Source |
|---|---|---|---|
| Cell line development | Mammalian cell-line generation; also for ADC antibodies under the Kyongbo MOU | — | [S27] |
| Process and analytical development | Upstream and downstream process development; analytical method development | — | [S9a][S27] |
| DS: mammalian, Songdo | Single-use (SUB/SUS) bioreactors | KIRS 2022: 1 × 1,000 L (Suite 1-1), 1 × 1,000 L (Suite 1-2), 1 × 500 L (Suite 2), 2 × 1,000 L (Suites 5 and 6), totalling 4,500 L. iM 2025 describes 4 × 1,000 L + 1 × 500 L. | [S4][S9] |
| DS: microbial, Songdo | Microbial fermentation (supports pDNA) | 1 × 500 L (Suite 3) | [S4][S9] |
| DP: fill/finish, Songdo Suite 4 | Liquid vials (2–50 mL) | 7,200 vials per hour | [S4] |
| DP: lyophilisation, Songdo Suite 4 | Freeze-dried vials | 30,000 vials per lot | [S4] |
| DP: pre-filled syringes, Songdo Suite 4 | PFS (1–3 mL) | 22,000 syringes per hour | [S4] |
| DS: mammalian, Osong | Single-use commercial line | 1 × 5,000 L + 2 × 1,000 L, totalling 7,000 L | [S4][S9] |
| DS: Osong expansion (under construction) | Commercial-scale line with automation and digital integrated management | 2 × 5,000 L, adding 10,000 L; start-up targeted for Dec 2026 (IBK: Q4 2026) | [S11][S2] |
| ADC CDMO package (with Kyongbo) | BINEX: antibody cell line, process, analytics, GMP production. Kyongbo: linker/payload screening and ADC conjugation. | Conjugation facility at Kyongbo targeted for H2 2027 | [S27] |
Named flagship programmes manufactured
| Programme | Owner | Stage / role | Source |
|---|---|---|---|
| Aptozma (tocilizumab biosimilar; reference product Actemra) | Celltrion | Commercial DS at Songdo; FDA cGMP approval Jan 2025; commercial production ramped in H2 2025 | [S2][S13] |
| Two undisclosed Celltrion biosimilar candidates | Celltrion | Clinical DS (technology transfer to Songdo and Osong), contract Jun 2025 | [S13] |
| GS071 (infliximab biosimilar) | Nichi-Iko / Aprogen | Commercial supply for Japan from 2017–2018 | [S23][S22] |
| GX-19 (COVID-19 DNA vaccine) | Genexine-led consortium | Co-development and manufacturing, 2020 | [S24] |
| Sputnik V (COVID-19 vaccine) | Korus consortium | Planned contract manufacturing at Osong in 2021 | [S20][S32a] |
| Undisclosed commercial biosimilar (KRW 20.8 bn) | "Global biopharma" | Commercial supply Dec 2025–Jun 2027 | [S15] |
| Undisclosed PPQ product (KRW 17.5 bn) | Korean biologics developer ("Company A") | PPQ, then commercial supply, to Sep 2026 | [S16][S2] |
Pricing for CDMO services is negotiated contract by contract and is not publicly disclosed.
Financial Narrative
Basis: K-IFRS consolidated statements.
-
FY2021–FY2024: IBK Securities and KIRS reproductions of DART statements [S2][S4].
-
FY2025 and H1 2026: Valueline/DataHero and Butler reproductions of DART [S7][S8][S30].
-
Ratios: computed by the analyst from those figures unless a source is stated.
Income statement
Sources by line:
-
Revenue, operating income and net income: Butler/DART [S7].
-
Gross profit: FY2021 from KIRS [S4]; FY2022–FY2025 from IBK [S2].
-
EBITDA: FY2021–FY2024 from IBK [S2]; FY2025 from Valueline [S8].
-
Pre-tax income: FY2021 from Medigate citing the DART disclosure (KRW 24.23 bn) [S37]; FY2022–FY2024 from IBK [S2]; FY2025 from Valueline [S8].
-
EPS: IBK [S2] and Valueline [S8].
Notes:
-
Diluted EPS is not separately disclosed in the sources reviewed; losses make dilution anti-dilutive in FY2024–FY2025.
-
FY2025 EBITDA of KRW 12.0 bn is the aggregator's figure. Adding back only depreciation and amortisation booked in cost of sales and SG&A gives about KRW 9.4 bn, so the true figure lies roughly between KRW 9 bn and 12 bn.
Margins and growth
Revenue CAGR for FY2021–FY2025 is 5.8%. Over FY2018–FY2025 (KRW 104.0 bn to KRW 168.5 bn) it is 7.1% [S4][S7]. Management has cited 11.6% average annual growth over ten years [S18].
Balance sheet
Sources: FY2021 from KIRS [S4] and IBK [S2]; FY2022–FY2025 from Valueline [S30].
Reconciliation notes:
Debt classification differs by source: IBK reports total borrowings of KRW 13 bn (FY2022), 35 bn (FY2023) and 66 bn (FY2024), and net debt of -21, +23 and +38 bn, because it treats the 2020 CB/EB as non-interest liabilities in some years.
The 7th EB: (KRW 15.5 bn face value, issued Nov 2025) does not appear as a bond line at FY2025 in the aggregator. It is probably carried in other financial liabilities. At H1 2026 it appears as a KRW 13.0 bn bond.
Latest interim balance sheet (30 Jun 2026) [S30]:
-
Total assets: KRW 312.1 bn
-
Cash: KRW 33.5 bn
-
Short-term borrowings: KRW 55.2 bn
-
Current portion of long-term debt: KRW 1.5 bn
-
Exchangeable bond: KRW 13.0 bn
-
Long-term borrowings: KRW 48.1 bn
-
Total debt: about KRW 117.8 bn; net debt about KRW 83.5 bn
-
Total liabilities: KRW 150.9 bn; equity: KRW 161.1 bn
-
Construction in progress: KRW 24.1 bn (up from KRW 13.0 bn at FY2025), mainly the Osong expansion
-
Accumulated other comprehensive loss: KRW 18.6 bn, largely fair-value declines on listed strategic stakes
Cash flow
Source: IBK Securities [S2]. KIRS gives FY2021 operating cash flow as KRW 28.1 bn and capex as KRW 11.8 bn [S4].
FY2025 full-year cash flow figures were not available in the sources reviewed. Interim data points:
H1 2025: operating cash flow of -KRW 24.7 bn, against -KRW 16.2 bn in H1 2024 [S10].
9M 2024: operating cash flow of -KRW 22.7 bn [S12].
Indicative FY2025 capex: PP&E rose from KRW 125.9 bn to KRW 139.3 bn, and construction in progress from KRW 5.7 bn to KRW 13.0 bn [S30], implying capex well above depreciation.
Ratios
Sources: ROE, ROA and ROIC for FY2021–FY2024 from IBK [S2]. FY2025 figures and the working-capital day counts are analyst calculations from year-end balances [S30] and cost of sales [S2][S8].
Net debt / EBITDA:
-
FY2022: 0.8x
-
FY2023: 3.3x
-
FY2024: not meaningful (negative EBITDA)
-
FY2025: about 6.1x, using KRW 12.0 bn EBITDA
Interest coverage (operating income / interest expense):
-
FY2021: 7.8x [S4]
-
FY2025: about -1.0x (interest expense KRW 4.45 bn [S8])
-
TTM to June 2026: about -4.6x (operating loss KRW 24.2 bn against interest expense of KRW 5.3 bn) [S8]
Trailing twelve months to 30 Jun 2026 [S8]
-
Revenue: KRW 157.3 bn
-
Gross profit: KRW 26.5 bn (gross margin 16.9%)
-
Operating loss: KRW 24.2 bn
-
EBITDA: -KRW 11.5 bn
-
Net loss: KRW 29.3 bn
-
EPS: -KRW 895
-
H1 2026: revenue KRW 73.1 bn (-13.3% YoY), operating loss KRW 18.2 bn, net loss KRW 24.6 bn [S6]
Commentary on trends, inflections and drivers
FY2021: regulatory shock absorbed by biologics growth. Revenue grew only 1.1%. Chemical revenue fell 9.7% after the MFDS suspension of six own products and 32 consignment generics, while biologics grew 19.7% [S4]. Net income nearly tripled to KRW 19.0 bn. This was not operational: about KRW 13.8 bn of non-cash valuation gains on the derivative components of the 2020 CB/EB drove it [S4][S37].
FY2022: peak profitability. Revenue rose 16.6% to KRW 156.7 bn and operating income reached KRW 17.2 bn (11.0% margin). Chemical revenue recovered as a base effect, and biologics benefited from Celltrion clinical and process-validation batches [S2][S31].
FY2023: margin collapse despite a record start. Q1 2023 was a record quarter (KRW 48.2 bn revenue, KRW 8.3 bn operating income) [S31]. However, biologics backlog fell from KRW 66.7 bn to KRW 28.4 bn as biotech clients struggled to raise funding [S9]. Full-year operating income was only KRW 1.0 bn. Gross margin fell 8.4 pp to 36.8% as the new Busan plant added fixed costs [S2][S17].
FY2024: trough year. Revenue fell 16.0% and the company posted an operating loss of KRW 30.8 bn. Management's explanation [S17]:
Chemical: revenue fell because of government regulation and policy changes.
Biologics: revenue fell because of biotech funding constraints, contract delays and FDA inspection preparation.
Costs: costs rose because of new Busan plant staffing and utilities, FDA consultants and staff, and replacement of ageing equipment.
Gross margin fell to 16.4%. Equity was kept roughly stable mainly by CB conversion: share count rose from 31.76m to 32.68m and capital surplus increased by about KRW 28 bn [S30].
FY2025: partial turnaround. Revenue rose 29.5% to KRW 168.5 bn. Biologics revenue rose about 79% to KRW 81.7 bn on Aptozma commercial DS and two Osong PPQ campaigns [S2]. The company was profitable at the operating level for Q1–Q3 (KRW 0.5 bn, 1.0 bn and 0.2 bn). Q4 swung to a KRW 6.3 bn operating loss because of an extended Songdo shutdown for commercial-grade line upgrades. Management says future shutdowns will move from annual to once every three years [S2]. Leverage rose: long-term borrowings of KRW 56.7 bn appeared, and net debt reached about KRW 72.6 bn [S30].
H1 2026: renewed deterioration. Revenue fell 11.2% YoY in Q1 and 15.1% in Q2, with operating losses of KRW 9.0 bn and 9.2 bn [S6]. Management's explanation for H1 2026 could not be retrieved from the sources reviewed. Plausible contributors, all analyst inference rather than disclosed fact:
-
Post-shutdown ramp timing at Songdo
-
Completion of PPQ campaigns without follow-on commercial volume yet
-
Pre-operating costs and fixed overhead ahead of Osong start-up
-
Higher interest expense (TTM KRW 5.3 bn)
-
Continued NHI price pressure on chemical products
Equity fell by KRW 26.3 bn in six months. The net loss was larger than the operating loss partly because financial losses included a KRW 3.7 bn financial-asset valuation loss (TTM) [S8].
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Sites |
|---|---|---|
Chemical pharmaceuticals (케미컬의약품) | Own-brand ETC/OTC products (about 120 SKUs), eye drops, contract chemical manufacturing | Busan (Saha-gu): No.1 plant plus new plant completed 2023 |
Biopharmaceuticals (바이오의약품) | Biologics CDMO (cell line, process, analytical development; DS and DP manufacturing), R&D and testing services | Songdo (KBCC, entrusted management); Osong (owned) |
Segment revenue
| Segment revenue | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Chemical pharmaceuticals revenue (KRW Bn) | 76.0 | 88.6 | 92.6 | 84.4 | 86.8 |
Biologics CDMO revenue (KRW Bn) | 58.4 | 68.1 | 62.2 | 45.6 | 81.7 |
Total revenue (KRW Bn) | 134.4 | 156.7 | 154.8 | 130.1 | 168.5 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Segment metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Chemical YoY growth (%) | -9.7 | 16.6 | 4.5 | -8.9 | 2.8 |
Biologics YoY growth (%) | 19.7 | 16.6 | -8.7 | -26.7 | 79.2 |
Chemical share of revenue (%) | 56.5 | 56.5 | 59.8 | 64.9 | 51.5 |
Biologics share of revenue (%) | 43.5 | 43.5 | 40.2 | 35.1 | 48.5 |
Revenue History
| Quarter | Biologics revenue (KRW Bn) | Chemical revenue (KRW Bn) | Total revenue (KRW Bn) | Operating income (KRW Bn) |
|---|---|---|---|---|
Q1 2024 | 8.6 | 21.1 | 29.7 | -10.6 |
Q2 2024 | 10.6 | 20.8 | 31.5 | -8.3 |
Q3 2024 | 13.1 | 19.8 | 32.9 | -4.7 |
Q4 2024 | 13.3 | 22.6 | 36.0 | -7.1 |
Q1 2025 | 17.9 | 21.9 | 39.8 | 0.5 |
Q2 2025 | 23.0 | 21.5 | 44.5 | 1.0 |
Q3 2025 | 23.9 | 21.4 | 45.4 | 0.2 |
Q4 2025 | 16.8 | 21.9 | 38.8 | -6.3 |
Q1 2026 | about 15.4 (est.) | about 19.9 (est.) | 35.3 | -9.0 |
Q2 2026 | about 16.3 (est.) | about 21.5 (est.) | 37.8 | -9.2 |
Income statement
| Income statement | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 134.4 | 156.7 | 154.8 | 130.1 | 168.5 |
Gross profit (KRW Bn) | 60.0 | 71.0 | 57.0 | 21.3 | 45.1 |
Operating income (KRW Bn) | 13.1 | 17.2 | 1.0 | -30.8 | -4.5 |
EBITDA (KRW Bn) | 19.0 | 25.0 | 11.0 | -18.0 | 12.0 |
Pre-tax income (KRW Bn) | 24.2 | 15.0 | 5.0 | -39.0 | -5.7 |
Net income (KRW Bn) | 19.0 | 12.4 | 4.6 | -35.2 | -3.3 |
EPS basic (KRW) | 601 | 392 | 147 | -1,097 | -99 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Margin and growth
| Margin and growth | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 1.1 | 16.6 | -1.2 | -16.0 | 29.5 |
Gross margin (%) | 44.6 | 45.2 | 36.8 | 16.4 | 26.8 |
Operating margin (%) | 9.7 | 11.0 | 0.6 | -23.7 | -2.7 |
EBITDA margin (%) | 14.1 | 15.9 | 7.1 | -13.8 | 7.1 |
Net margin (%) | 14.1 | 7.9 | 3.0 | -27.1 | -1.9 |
Balance Sheet
| Balance sheet | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (KRW Bn) | 272.5 | 298.4 | 257.0 | 279.4 | 311.4 |
Cash and cash equivalents (KRW Bn) | 50.1 | 31.1 | 8.2 | 25.7 | 18.4 |
Short-term financial assets (KRW Bn) | 3.7 | 3.9 | 3.5 | 3.2 | 2.4 |
Short-term borrowings (KRW Bn) | 5.0 | 3.2 | 28.0 | 59.9 | 33.0 |
Current portion of long-term debt (KRW Bn) | 0.0 | 8.5 | 1.2 | 1.3 | 3.7 |
Short-term bonds incl. CB/EB (KRW Bn) | 0.0 | 42.9 | 18.8 | 0.0 | 0.0 |
Non-current bonds (KRW Bn) | 43.6 | 0.0 | 0.0 | 0.0 | 0.0 |
Long-term borrowings (KRW Bn) | 0.0 | 0.0 | 0.0 | 0.0 | 56.7 |
Total debt ex-leases (KRW Bn) | 48.6 | 54.6 | 48.0 | 61.2 | 93.4 |
Net debt (KRW Bn) | -5.2 | 19.6 | 36.3 | 32.3 | 72.6 |
Total liabilities (KRW Bn) | 91.3 | 106.1 | 75.7 | 97.8 | 124.0 |
Total equity (KRW Bn) | 181.2 | 192.3 | 181.3 | 181.6 | 187.5 |
Intangible assets (KRW Bn) | 10.2 | 18.3 | 23.8 | 21.1 | 18.8 |
Goodwill (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Working capital (KRW Bn) | 75.6 | 10.7 | 6.3 | 0.4 | 50.2 |
Cash flow
| Cash flow | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Operating cash flow (KRW Bn) | 29 | 17 | 4 | -9 |
Capex: PP&E additions (KRW Bn) | 12 | 26 | 8 | 10 |
Free cash flow (KRW Bn) | 17 | -9 | -4 | -19 |
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 |
Share buybacks (KRW Bn) | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | 10.8 | 6.7 | 2.5 | -19.3 | -1.8 |
ROA (%) | 7.0 | 4.3 | 1.7 | -13.1 | -1.1 |
ROIC approx. (%) | 14.1 | 9.6 | 3.2 | -20.3 | -1.7 |
Current ratio (x) | 3.31 | 1.11 | 1.09 | 1.00 | 1.80 |
Total debt / equity (%) | 26.8 | 28.4 | 26.5 | 33.7 | 49.8 |
Liabilities / equity (%) | 50.4 | 55.2 | 41.7 | 53.8 | 66.1 |
Asset turnover (x) | 0.50 | 0.55 | 0.56 | 0.49 | 0.57 |
Receivable days | 47 | 51 | 33 | 46 | 48 |
Inventory days | 112 | 124 | 105 | 104 | 118 |
Payable days | 18 | 15 | 7 | 16 | 13 |
Cash conversion cycle (days) | 141 | 160 | 131 | 134 | 153 |
Contract Details
| Contract (date) | Value (KRW Bn) | Counterparty type | Implied geography |
|---|---|---|---|
24 Sep 2024 | 17.4 | Domestic biologics developer (PPQ) | Korea |
19 Nov 2024 | 15.8 | Pharmaceutical company | — |
30 Jun 2025 | 16.2 | Global pharma (repeat customer) | Likely non-Korean |
8 Sep 2025 | 20.8 | Global biopharma (repeat customer) | Likely non-Korean; US and EU market entry cited |
“—” = not publicly disclosed.
Share price metric
| Share price metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Year-end share price (KRW) | 15,200 | 11,550 | 8,950 | 18,340 | 14,980 |
Year-end market cap (KRW Bn) | 482 | 366.8 | 284.3 | 599.4 | 489.6 |
Year-end P/B (x) | 2.7 | 1.9 | 1.57 | 3.31 | 2.61 |
Change by Period
| Period | Change |
|---|---|
Year to date 2026 | -62% (KRW 14,980 to KRW 5,690) |
Since end-2023 (about 2.8 years) | -36% |
Since end-2021 (about 4.8 years) | About -63% |
1-year | About -66% (vs KRW 16,340 at 30 Sep 2025 [S8]) |
52-week range | KRW 5,500 – 19,200 [S29] |
All-time context | Closed at KRW 36,000 on 30 Aug 2020 during the COVID-era CDMO rally [S20] |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Price | KRW 5,690 | [S8] |
Market capitalisation | KRW 194.8 bn | [S8] |
Enterprise value | About KRW 278 bn | Market cap plus H1 2026 net debt of KRW 83.5 bn |
P/E (TTM) | Not meaningful (EPS -KRW 895; aggregator shows -6.66x) | [S8] |
P/B | 1.21x (book value per share KRW 4,926) | [S8][S30] |
EV/Sales (TTM) | About 1.8x | TTM revenue KRW 157.3 bn |
EV/EBITDA (TTM) | Not meaningful (TTM EBITDA -KRW 11.5 bn) | [S8] |
ROE (TTM) | -18.2% | [S7][S8] |
Capital Instruments
| Instrument | Amount (KRW Bn) | Maturity / terms |
|---|---|---|
Short-term borrowings | 55.2 | Within 12 months |
Current portion of long-term debt | 1.5 | Within 12 months |
7th exchangeable bond | 13.0 carrying (15.5 face) | Zero coupon; exchange at 115% of reference price; tenor and put dates not disclosed in sources |
Long-term borrowings | 48.1 | Beyond 12 months; lenders and tenors not disclosed |
Lease and other long-term financial liabilities | 2.6 | Various |
Analyst Conclusions
Management guidance and consensus
No quantified guidance has been issued. Management's qualitative messages:
-
Revenue growth to resume once Osong is completed (Dec 2026 target) and certified by FDA/EMA [S10][S11].
-
Shutdown frequency to be cut to once every three years [S2].
-
A backlog of more than KRW 100 bn was cited in Sep 2025 [S10]; the FY2025 year-end bio backlog was KRW 66.6 bn per IBK [S2].
Consensus (four brokers) implies a target of about KRW 13,000 [S7].
Biologics order backlog history
| Backlog metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Biologics CDMO order backlog (KRW bn) | 61.9 | 66.7 | 28.4 | 64.3 | 66.6 |
Source: IBK Securities [S2] and iM Securities [S9]. The FY2020 backlog was KRW 33.7 bn.
Bull case
-
Commercial transition. FY2025 biologics revenue of KRW 81.7 bn was achieved with the Songdo shutdown in Q4. A full year of commercial Aptozma and the KRW 20.8 bn global biosimilar contract running to mid-2027 supports a return of biologics revenue towards KRW 90–100 bn once utilisation normalises [S2][S15].
-
Operating leverage from Osong. The +10,000 L expansion roughly doubles capacity [S11]. In FY2021, at high utilisation, biologics margins reached 22.8% [S4]. If Osong passes FDA/EMA inspection in late 2026 or 2027 and fills, the margin profile could revert towards FY2021–FY2022 levels (consolidated operating margin 10–11%).
-
Low valuation. At about 1.2x book and 1.8x EV/Sales, the stock is priced for distress. A strategic stake portfolio worth tens of billions of won provides asset backing [S5][S8][S12].
Bear case
-
Earnings deterioration. The Q1–Q2 2026 operating losses (-KRW 9.0 bn and -9.2 bn) came after the commercial ramp. This suggests the cost base (payroll at 23.2% of revenue, FDA-grade quality systems) is too heavy for current volumes [S5][S6].
-
Balance-sheet strain. Net debt doubled from KRW 32 bn (FY2024) to about KRW 84 bn (H1 2026) while equity fell to KRW 161 bn. Further capex for Osong and the planned follow-on phases may require dilutive equity or CBs [S30][S10].
-
Structural concentration and tenure risk. A few contracts drive revenue swings of ±15%. The core FDA-approved site (Songdo) is government property under a contract ending Nov 2029 [S4][S15].
Key catalysts and monitorables (next 12 months)
-
Q3 2026 results (mid-Nov 2026): whether revenue stabilises above KRW 40 bn per quarter and losses narrow.
-
Osong commissioning (Dec 2026) and the timing of FDA/EMA pre-approval inspections.
-
New single supply-contract disclosures, especially a follow-on commercial order after the KRW 17.4 bn PPQ contract (ending Sep 2026) and the KRW 16.2 bn contract (ending Jul 2026).
-
Financing actions: new EB/CB, equity raises, or sales of strategic stakes.
-
Identity of the 2026 large-holding filers and any change-of-control activity.
-
Celltrion biosimilar approvals and volumes, which affect Songdo utilisation.
-
Progress on the KBCC contract beyond 2029.
-
US Biosecure Act implementation and US pharma tariff policy.
Concluding analyst verdict
BINEX is a structurally interesting but financially fragile company. It is a sub-scale Korean CDMO with credentials that much larger rivals took years to obtain:
-
Songdo holds FDA, EMA and PMDA approvals.
-
It has commercial supply experience with a blockbuster-reference biosimilar (Aptozma).
-
It has a decade-long record with Korean biotechs.
FY2025 showed what this can produce. Biologics revenue nearly doubled to KRW 81.7 bn, and the group was profitable at the operating level for three quarters.
The subsequent reversal is the central problem. Revenue fell 11–15% YoY in Q1–Q2 2026, and quarterly operating losses of about KRW 9 bn returned. Gross margin has fallen to about 17% TTM, and net debt has risen to about KRW 84 bn against KRW 161 bn of equity. All of this happened while the company is committing KRW 55.7 bn to Osong. The chemical business, which once funded biologics, now contributes little profit because of NHI price cuts. The 2021 MFDS manufacturing-integrity case remains a reputational burden in an industry built on quality trust. The government ownership of Songdo, with the contract ending in 2029, is an underappreciated long-dated risk.
At roughly 1.2x book and 1.8x EV/Sales, much of this is priced in. The equity is now effectively an option on three things:
-
Osong commissioning and FDA/EMA approval on time.
-
Converting the KRW 60–70 bn biologics backlog into sustained commercial volumes beyond Celltrion.
-
Funding that bridge without heavy dilution.
Success on all three would justify a re-rating towards broker targets of KRW 13,000–14,000. Failure on any one, particularly financing, risks further equity erosion.
Stance: high-risk, catalyst-dependent; Speculative / Neutral pending Q3–Q4 2026 evidence of loss narrowing and Osong inspection timing. The most decision-useful data points will be the Q3 2026 gross margin, any new commercial supply contract larger than KRW 15 bn, and the terms of the next financing.
SOURCES REGISTER
S1: BINEX Q1 2026 quarterly report (42nd period), KIND/DART — 15 May 2026 — https://kind.krx.co.kr/external/2026/05/15/002234/20260515004986/11013.htm
S2: IBK Securities, "Binex: preparing to expand commercial production" (Company Update) — 18 Mar 2026 — https://file.alphasquare.co.kr/media/pdfs/company-report/20260317091752683_ko.pdf
S3: IBK Securities, Binex 2Q25 Review — 19 Aug 2025 — https://file.alphasquare.co.kr/media/pdfs/market-report/ (바이넥스2Q2520250819IBK투자증권)
S4: Korea IR Council (KIRS) Research Center, Binex company analysis — 14 Jul 2022 — https://ssl.pstatic.net/imgstock/upload/research/company/1657754088285.pdf
S5: ETF Shopping, Binex shareholders/company page (extracted from DART FY2021–FY2025 business reports) — Updated Mar/Sep 2026 — https://etfshopping.com/stock/053030/company
S6: ETF Shopping, Binex earnings history (DART periodic reports) — Updated 14 Sep 2026 — https://etfshopping.com/stock/053030/earnings
S7: Butler.works, Binex financial dashboard and disclosure list — Oct 2026 — https://www.butler.works/ko/companies/00216027
S8: Valueline (DataHero), Binex consolidated income statement (TTM) — 15 Oct 2026 — https://www.valueline.co.kr/finance/income/053030
S9: iM Securities, Binex Company Brief — 14 Apr 2025 — https://file.alphasquare.co.kr/media/pdfs/company-report/_14072203-053030.pdf
S9a: IntuitionLabs company directory: Binex (AI-generated; used only for non-critical items) — 2026 — https://www.intuitionlabs.ai/companies/cdmo/binex-co-ltd
S10: Dealsite, "Binex Osong expansion: KRW 55.7 bn funding in focus" — 24 Sep 2025 — https://dealsite.co.kr/articles/148598
S10a: Statbase, Binex company card (ISIN, IPO date; dated management list) — 2026 — https://statbase.ru/companies/binex/
S10b: CB Insights, Binex profile (SK bioscience hire news, Dec 2025) — 2025 — https://www.cbinsights.com/company/binex
S10c: CB Insights, Binex patents listing — 2025 — https://www.cbinsights.com/company/binex
S10d: IMAPAC, "South Korea's Biologics CDMO: A Strategic Industry Guide" — 2025 — https://info.imapac.com/content/south-koreas-biologics-cdmo-a-strategic-industry-guide/
S11: BizWatch, "Binex adds 10,000 L at Osong" — 22 Sep 2025 — https://news.bizwatch.co.kr/article/healthcare/2025/09/22/0007
S12: Dealsite, "Binex Osong expansion funding in focus" — 14 Mar 2025 — https://dealsite.co.kr/articles/138022
S13: Dealsite, "Binex wins additional Celltrion CMO contract" — 16 Jun 2025 — https://dealsite.co.kr/articles/143075
S14: Dealsite, "Binex KRW 16.2 bn biologics supply contract" — 30 Jun 2025 — https://dealsite.co.kr/articles/143815
S15: DigitalToday AI Gongsi, KRW 20.8 bn supply contract (full disclosure table); Dealsite 8 Sep 2025 — 8 Sep 2025 — https://www.digitaltoday.co.kr/aigongsi/amp/2444/binex-global-bio-pharmaceutical-supply-contract
S16: Medigate News, KRW 17.5 bn PPQ contract — 24 Sep 2024 — https://medigatenews.com/news/2344265341
S17: SmartToday, "Binex FY2024 operating loss" — 5 Mar 2025 — https://www.smarttoday.co.kr/ko-kr/articles/74338
S18: SmartToday, "Binex Osong CDMO investment agreement" — 14 Feb 2025 — https://www.smarttoday.co.kr/ko-kr/articles/72674
S19: IB Tomato (Newstomato), Binex EB issuance — Nov 2025 — https://newstomato.com/ReadNews.aspx?no=1279691
S19a: Hankyung Eureka column (Biosecure Act beneficiary) — 3 Jun 2025 — https://eureka.hankyung.com/insight/detail/12670
S20: Dailypharm 2021 series on the MFDS manufacturing case (articles 53697, 53655, 53686, 53663, 53500, 53259, 53181, 53145, 53621, 53670) — Mar 2021 — https://dailypharm.com/user/news/53181 (and related)
S21: Dailypharm, 2007 R&D profile and 2008 JLC acquisition (company history) — 2007–2008 — https://www.dailypharm.com/user/news/236671 ; https://m.dailypharm.com/user/news/226178
S22: Newstomato small-cap report (Nichi-Iko investment) — 27 Oct 2014 — https://newstomato.com/ReadNews.aspx?no=508070
S23: Dealsite/Paxnet, GS071 and customer expansion — 31 May 2018 — https://dealsite.co.kr/articles/21074
S24: Dealsite, KRW 50 bn CB/EB with Kwangdong, Genexine, ABL Bio — 28 Sep 2020 — https://dealsite.co.kr/articles/65670
S25: Dailypharm (Tongfang KRW 211 bn placement); ACN Newswire (Tongfang Kontafarma announcement) — 29 Nov / 16 Dec 2016 — https://m.dailypharm.com/user/news/105832 ; https://www.acnnewswire.com/press-release/english/34073/
S26: Kormedi / Medigate / Ajunews, GC Green Cross CMO MOU — 8 Jan 2021 — https://kormedi.com/1330795/
S27: Medifonews / Sateconomy, Kyongbo–Binex ADC CDMO MOU — 19–20 Feb 2025 — https://www.medifonews.com/news/article.html?no=199884
S28: Dailypharm, Kwangdong–Precision Biosensor (Binex CEO board seat; 2020 Kwangdong stake) — 4 Oct 2024 — https://www.dailypharm.com/user/news/12828
S29: Investing.com (Japan), Binex quote and holders — 23 Aug 2026 — https://jp.investing.com/equities/binex-co-ltd
S29a: Morningstar (AU), Binex business description — 2026 — https://www.morningstar.com.au/investments/security/xkrx/053030
S30: Valueline (DataHero), Binex consolidated balance sheet FY2022–H1 2026 — 15 Oct 2026 — https://www.valueline.co.kr/finance/balancesheet/053030
S31: Sangsangin Securities, Binex 1Q23 report — 19 May 2023 — https://files-scs.pstatic.net/2023/05/19/Ae5aJ6s7gG/
S32: SK Securities, Binex 1Q23 review — 13 May 2023 — https://file.alphasquare.co.kr/media/pdfs/company-report/20230513144531313_0_ko.pdf
S32a: SK Securities, Binex (Sputnik V context) — 27 May 2021 — https://file.alphasquare.co.kr/media/pdfs/company-report/SK20210527바이넥스.pdf
S33: Kormedi, SK bioscience Q2 2026 results (FY2025 figures) — Aug 2026 — https://kormedi.com/2844648/
S34: DigitalToday AI Gongsi, Binex holding in EasyCareTech — 6 Nov 2025 — https://www.digitaltoday.co.kr/aigongsi/4896/major-shareholder-binex-easycaretech-10-percent-stake
S35a: Remember job posting, Binex Osong production support team lead — Dec 2025 — https://career.rememberapp.co.kr/job/posting/280026
S36: Dealsite, "Why Binex is expanding Osong" (FDA approval Jan 2025) — 12 Mar 2025 — https://dealsite.co.kr/articles/137933
S37: Medigate News, Binex FY2021 results disclosure — 2 Mar 2022 — https://medigatenews.com/news/2404903948
Data limitations:
-
KIND/DART primary documents could not be fetched directly because of bot protection. FY2025 and 2026 statement items therefore rely on aggregators that reproduce DART consolidated statements.
-
Items marked "not publicly disclosed" were not found in the retrievable sources. They may appear in the full FY2025 business report on DART (rcpNo 20260313001124):
-
Auditor
-
Board composition
-
Individual compensation
-
Total R&D
-
Geographic split
-
ESG ratings
-
Debt tenors
-
Management's explanation of H1 2026 results
-
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background |
|---|---|---|
Lee Hyuk-jong (이혁종) | CEO / Representative Director | CEO by at least Nov 2016. Signs current filings. Born 1969 per an aggregator. Also a non-executive director of Precision Biosensor (a Kwangdong-controlled company) since Sep 2024. Holds 0.40% of BINEX. |
Yang Jae-cheol (양재철) | Head of Management Administration Division (경영관리본부장); filing officer | — |
Cho Jin-seop (조진섭) | Head of CMO Business Office (as of Jan 2021) | — |
Jeong Myung-ho (정명호) | Former CEO | Appointed Jul 2010 |
Lee Baek-chun (이백천) | Former Chairman / CEO | Acquired the company in 1985; chairman through the 2000s |
“—” = not publicly disclosed.
Major Shareholders
| Holder | Stake (%) | Basis / date |
|---|---|---|
The Able Co., Ltd. (formerly Binex Holdings) | 9.18 | FY2025 business report |
Able Partners Co., Ltd. (related party) | 1.18 | FY2025 |
Lee Hyuk-jong (CEO, related party) | 0.40 | FY2025 |
Largest shareholder group total | 10.76 | FY2025 |
Samsung Asset Management | 5.20 (IBK, Mar 2026); 4.29 (Investing.com, Aug 2026) | 5% filing / aggregator |
Kwangdong Pharmaceutical and one related party | 5.01 | 5% filing, 10 Oct 2024 |
National Pension Service | 2.01 | End-2024 |
Treasury shares | about 2.56 (partly pledged as the 7th EB exchange pool of 836,512 shares) | 2026 |
Minority shareholders (52,889 holders) | 79.07 | FY2025 |
Foreign ownership | 4.1 | 17 Mar 2026 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs BINEX | Source / note |
|---|---|---|---|
Biologics CDMO (Korea) | Samsung Biologics | Very-large-scale (multi-hundred-thousand-litre) commercial CDMO for big pharma. KIRS deems it not a direct competitor because of scale and customer mix. | [S4] |
Biologics CDMO (Korea) | Celltrion / Celltrion BioSolutions | Customer and potential in-sourcing competitor | [S10d] |
Biologics CDMO (Korea) | Lotte Biologics | Large-scale entrant (Syracuse, US, plus Songdo build-out) | [S10d] |
Biologics CDMO (Korea) | SK bioscience | Vaccines and biologics CDMO (Andong L-House); FY2025 revenue KRW 651.4 bn | [S10d][S33] |
Biologics CDMO (Korea) | Prestige Biologics | Mid-scale Osong-based CDMO | [S10d] |
Biologics CDMO (Korea) | GC Biopharma | Fill/finish CMO; also a partner | [S10d][S26] |
Biologics CDMO (Korea) | GeneMedicine, Kolon Biotech, STgen Bio, Quratis | Niche, gene-therapy and vaccine CDMOs | [S10d] |
Biologics CDMO (global) | WuXi Biologics | Mid-to-large global CDMO (about 43,000 L in 2022 per KIRS); Biosecure Act exposure | [S4] |
Biologics CDMO (global) | Lonza, Fujifilm Diosynth, AGC Biologics | Global multi-site CDMOs | Industry knowledge; no figures relied on |
Chemical (Korea) | Domestic generic and contract chemical manufacturers (dozens of NHI generic players) | Price-regulated, fragmented market | [S4] |
Peer Comparison FY2025
| Metric | BINEX FY2025 | Samsung Biologics FY2024 | SK bioscience FY2025 | WuXi Biologics FY2024 |
|---|---|---|---|---|
Revenue | KRW 168.5 bn | KRW about 4,547 bn | KRW 651.4 bn | RMB about 18.7 bn |
Revenue growth YoY | +29.5% | About +23% | n.d. in sources | About +10% |
Operating margin | -2.7% | About 29% | -19.0% (operating loss KRW 123.5 bn) | n.d. in sources |
R&D / revenue | about 0.7% (SG&A-booked only) | — | — | — |
Recent Developments
The register above is complete for verifiable items.



